EP4698557A2 - C3d-immuntherapien - Google Patents

C3d-immuntherapien

Info

Publication number
EP4698557A2
EP4698557A2 EP24793419.3A EP24793419A EP4698557A2 EP 4698557 A2 EP4698557 A2 EP 4698557A2 EP 24793419 A EP24793419 A EP 24793419A EP 4698557 A2 EP4698557 A2 EP 4698557A2
Authority
EP
European Patent Office
Prior art keywords
cancer
cells
subject
recombinant
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24793419.3A
Other languages
English (en)
French (fr)
Inventor
Marilia CASCALHO
Jeffrey PLATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of EP4698557A2 publication Critical patent/EP4698557A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24793419.3A 2023-04-17 2024-04-17 C3d-immuntherapien Pending EP4698557A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363459844P 2023-04-17 2023-04-17
PCT/US2024/025032 WO2024220570A2 (en) 2023-04-17 2024-04-17 C3d immunotherapies

Publications (1)

Publication Number Publication Date
EP4698557A2 true EP4698557A2 (de) 2026-02-25

Family

ID=93153518

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24793419.3A Pending EP4698557A2 (de) 2023-04-17 2024-04-17 C3d-immuntherapien

Country Status (2)

Country Link
EP (1) EP4698557A2 (de)
WO (1) WO2024220570A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580274B2 (en) * 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
US11214603B2 (en) * 2016-04-27 2022-01-04 The Regents Of The University Of Michigan C3D cellular and acellular vaccines for the prevention and treatment of cancer

Also Published As

Publication number Publication date
WO2024220570A3 (en) 2025-02-27
WO2024220570A2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
Marin et al. Cellular senescence is immunogenic and promotes antitumor immunity
EP3362074B1 (de) Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
US10550191B2 (en) Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
JP2023529026A (ja) Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用
WO2020006385A2 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20170130271A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP5291641B2 (ja) 癌抗原及びその利用
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
US20250043270A1 (en) A method of treating acute myeloid leukemia
KR20210102331A (ko) 암 및 기타 질환의 진단 및 치료를 위한 종양 촉진 암종 관련 섬유아세포의 식별 및 표적화
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
JP7598661B2 (ja) Ｃｃｌ２８走化性経路を遮断することによる胃がんの治療方法
ES2728998T3 (es) Nuevo antígeno de cáncer EEF2
WO2019014664A1 (en) MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
EP3706751A1 (de) Zusammensetzungen und verfahren zur behandlung von krebs mit dominant-negativen rhoa-formen
JP2022513082A (ja) 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
US20060216231A1 (en) Methods for diagnosing and treating tumors and suppressing cd promoters
US20240288425A1 (en) Selection of patients for combination therapy
WO2024220570A2 (en) C3d immunotherapies
US20210169913A1 (en) Fcrl6 and its uses related to cancer
EP2756002A2 (de) Zusammensetzungen und verfahren im zusammenhang mit der reparatur von dns-schäden
CN114555636A (zh) 针对犬cd20的单克隆抗体或抗体片段
WO2025020931A1 (en) Cdk20 in cancer diagnosis and therapy
WO2024097096A1 (en) Methods for treating and preventing b cell disorders
CN106554962A (zh) 过表达gpr160的癌症的预防、诊断和治疗

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251010

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR